suPAR in COVID-19 and emergency medicine in the Caribbean

Fri Jun 26 2020

By: Jérôme Bouffel, ViroGates

suPAR News Vol. 3, June 2020

Papa Gueye, MD, PhD, (Fig. 1, left) is heading the Emergency Medical Service Martinique French West Indies at the Centre Hospitalier Universitaire (CHU) de Martinique (Fig. 2). He is also President of the Collège Carribéen de Médecine d’Urgence and of the 5ème Congrès des Urgences et SAMU des Outre-Mers.

Papa Gueye, MD, PhD, leads the Emergency Medical Service at the Centre Hospitalier Universitaire (CHU) de Martinique in the French West Indies and holds positions as President of the Collège Carribéen de Médecine d’Urgence and the 5ème Congrès des Urgences et SAMU des Outre-Mers (Fig. 1, left). The CHU of Martinique, a public hospital, operates across seven sites, including three with laboratory activity. Mael Padelli, a biochemist and PhD researcher, works at one of the Core Labs in the Pierre Zobda Quitman hospital in Fort-de-France, which boasts a fully automated Abbott production line (Fig. 1, right).

Papa Gueye, Mael Padellí

“To minimize the spread of COVID-19 and to be
able to identify patients in need of extra attention, a study of suPAR in patients suspected with COVID-19 was initiated.”

MD, PhD, heading the Emergency Medical Service Martinique French West Indies at the Centre Hospitalier Universitaire (CHU) de Martinique
suPAR News Vol. 3, June 2020

Dr. Gueye has a keen interest in exploring new biomarkers. His interest in suPAR, a potential biomarker for emergency triage, grew after attending the National French Urgences conference in Paris in 2019. There, he discussed suPAR’s utility with Prof. Yann-Erick Claessens, Head of the ED at Monaco Hospital, at the ViroGates booth. He decided to introduce suPAR in two ways: as a prognostic tool for Dengue Fever in the local population and as a triage marker in the emergency department (ED).

The CHU of Martinique integrated suPAR testing into their Core Lab using an Abbott Architect 16000 and at Mangot-Vulcin Hospital using a Roche cobas c502. However, the outbreak of the COVID-19 pandemic required an immediate response to prevent its spread on the island and identify patients requiring urgent care. The hospital initiated a suPAR study in patients suspected of having COVID-19, setting up specialized sampling sites to control the virus’s spread.

The findings from this COVID-19 study will inform future decisions on the routine use of suPAR for patient triage at the CHU of Martinique. The hospital plans to present all results from their suPAR testing at the 5ème Congrès des Urgences et SAMU des Outre-Mers in December 2020.

Read more articles like this in the third edition of our magazine suPAR News.
Hospital

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates